These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 34320163)

  • 1. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Stephens DM; Byrd JC
    Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
    Wu J; Zhang M; Liu D
    Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
    Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Nakhoda S; Vistarop A; Wang YL
    Br J Haematol; 2023 Jan; 200(2):137-149. PubMed ID: 36029036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
    McCulloch R; Eyre TA; Rule S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
    Leukemia; 2024 Jul; 38(7):1570-1580. PubMed ID: 38454120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
    Thompson PA; Tam CS
    Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK inhibitors in CLL: second-generation drugs and beyond.
    Tam C; Thompson PA
    Blood Adv; 2024 May; 8(9):2300-2309. PubMed ID: 38478390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.